Description:
Cardiovascular diseases, including those affecting the heart and brain’s blood vessels, are the leading cause of death globally. With the incidence of cardiovascular disease rising sharply, the demand for cardiac markers is increasing, driving constant research and development for improved diagnostics.
Kalorama Information’s World Market for Cardiac Markers (POC and Lab-Based), 2021-2026 provides crucial insights into the current state and future trends of the cardiac marker market. The report covers why cardiac markers are in huge demand and are a constant subject of research for improvement. This report is indispensable for business planning, market strategy development, and staying informed about advancements in cardiac diagnostics.
Report Highlights:
- Market Overview:
- Cardiac biomarkers are critical substances released into the bloodstream when the heart is damaged or stressed.
- These biomarkers are essential for diagnosing and managing chronic heart failure, assessing treatment options, and monitoring patient progress.
- Significance of Cardiac Biomarkers:
- Used in acute care settings to diagnose cardiac events and in evaluating the risk of future cardiovascular events.
- Traditional markers include BNP, troponin, and myoglobin, while cholesterol tests are used for risk evaluation.
- New biomarkers like cardiac troponin, Galectin-3, Copeptin, ST2, and MR-proADM show promise for enhancing traditional diagnostic methods.
- Comprehensive Cardiac Risk Assessment:
- A multidisciplinary approach includes biomarkers such as troponins (cTnI and cTnT), BNP, NT-proBNP, GFAP, H-FABP, LDH isoenzymes, D-dimer, IMA, MPO, myoglobin, and sCD40L.
- Cardiac risk work-ups typically include a mix of lipids and inflammation markers like cholesterol, HDL, LDL, homocysteine, fibrinogen, C-reactive protein, lipoprotein fractions, and D-Dimer tests.
- Market Dynamics:
- An aging population and technological advancements are driving the growth of the cardiac marker market.
- Approximately 2.6 million people die of cardiovascular disease each year in the seven leading countries (France, Germany, Italy, Japan, Spain, UK, and the U.S.), concentrating the market in developed regions.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Cardiac Marker Diagnostic Sales, by Test Type, 2021-2026 ($ millions)
| Type | 2021 | % Mkt | 2026 | % Mkt | CAGR |
| Lab-based Cardiac Markers | $XX Million | XX% | $XX Million | XX% | XX% |
| Point-of-Care Cardiac Markers | $XX Million | XX% | $XX Million | XX% | XX% |
| Total | $XX Million | XX% | $XX Million | XX% | XX% |
Source: Kalorama Information
